<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265057</url>
  </required_header>
  <id_info>
    <org_study_id>Adherex Protocol # AHX-01-004</org_study_id>
    <nct_id>NCT00265057</nct_id>
  </id_info>
  <brief_title>Study of ADH-1 Given Intravenously to Patients With Solid Tumors</brief_title>
  <official_title>Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Weekly in 3 Week Cycles by Intravenous Infusion in Patients With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX-01-004)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adherex Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adherex Technologies, Inc.</source>
  <brief_summary>
    <textblock>
      N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer&#xD;
      progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study&#xD;
      will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a&#xD;
      protein biomarker called N-cadherin. This study will identify the amount of ADH-1 that&#xD;
      subjects can tolerate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADH -1 (Exherin™)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Male and female patients &gt; or = 18 years of age with a solid tumor(s) refractory to&#xD;
             standard curative therapy or for which no curative therapy exists. Study currently&#xD;
             enrolling only patients with non-small cell lung cancer or advanced ovarian cancer to&#xD;
             the safety expansion phase.&#xD;
&#xD;
          -  Clinically or radiologically documented measurable disease.&#xD;
&#xD;
          -  Immunohistochemical evidence of N-cadherin expression (at least 1+ positive) in&#xD;
             archived or fresh tumor tissue&#xD;
&#xD;
          -  Adequate performance status and organ function, as evidenced by hematological and&#xD;
             biochemical blood testing and electrocardiogram (ECG)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Receipt of ADH-1 prior to this clinical study&#xD;
&#xD;
          -  Chemotherapy, radiotherapy, or any other investigational drug within 30 days before&#xD;
             study entry&#xD;
&#xD;
          -  History of primary brain tumors or brain metastases (known or suspected) unless any&#xD;
             lesions have completely resolved following appropriate treatment and there has been no&#xD;
             recurrence for at least 6 months. History of spinal cord compression. History of&#xD;
             tumors that have shown clinically significant evidence of active bleeding (e.g., gross&#xD;
             hemoptysis, hematemesis, hematuria, melena, or bleeding superficial tumor) within 12&#xD;
             weeks before study entry.&#xD;
&#xD;
          -  Stroke, major surgery, or other major tissue injury within 30 days before study entry&#xD;
&#xD;
          -  History of congestive heart failure, myocardial infarction, angina, life threatening&#xD;
             arrhythmias, significant electrocardiogram (ECG) abnormalities, or known&#xD;
             hypercoagulable states&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Europeo di Oncologia</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.adherex.com</url>
    <description>Adherex Technologies Inc. Corporate Homepage</description>
  </link>
  <verification_date>December 2010</verification_date>
  <study_first_submitted>December 13, 2005</study_first_submitted>
  <study_first_submitted_qc>December 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2005</study_first_posted>
  <last_update_submitted>December 27, 2010</last_update_submitted>
  <last_update_submitted_qc>December 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2010</last_update_posted>
  <keyword>Cancer;</keyword>
  <keyword>Tumors;</keyword>
  <keyword>Neoplasms;</keyword>
  <keyword>Anticarcinogenic Agents;</keyword>
  <keyword>Antineoplastic Agents;</keyword>
  <keyword>Cadherins;</keyword>
  <keyword>Non-Small-Cell Lung Carcinoma;</keyword>
  <keyword>Ovarian Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

